In another study, Liang et al. discovered that Schisandrin Lignans Enhancer (SLE) could increase the exposure of ginsenoside Rb2 by inhibiting the activity and expression of P-glycoprotein (P-gp), thereby decreasing its efflux rate in Caco-2 and L-MDR1 cells. Here, PGP is linked to systemic lupus erythematosus.